BPIFB4 and cardiomyopathy: This is expected as platelets are key cellular players in those conditions, e.g., atherosclerosis, cardiomyopathy, and diabetic pro-thrombotic phenotype [19] in which the treatment with LAV-BPIFB4 resulted most effective to ameliorate both endothelial and cardiac function, mainly blunting inflammatory background [11, 12].